CMR: complete resolution of 18F-FDG uptake within measurable target lesion so that it is less than mean liver activity and indistinguishable from surrounding background blood-pool levels. Disappearance of all other lesions to background bloodpool levels. Percentage decline in SUL should be recorded from measurable region, as well as (ideally) time in weeks after treatment was begun. No new 18F-FDG-avid lesions in pattern typical of cancer. If progression by RECIST, must verify with follow-up.